News

Dr. Eugenia Oviedo-Joekes

Dr. Eugenia Oviedo-Joekes awarded a CIHR New Investigator Award

Congratulations to Dr. Eugenia Oviedo-Joekes who has been awarded a CIHR New Investigator Award.

Second year MHA students wrap up their course work

Second year MHA students wrap up their course work

Congratulations to our MHA students who have wrapped up their course work in the MHA program.

Transit investments lead to healthier people

Transit investments lead to healthier people

A new report spearheaded by UBC’s Lawrence Frank explores the relationship between transportation and health care.

Patricia Janssen

Dr. Patricia Janssen presents the Patricia Janssen Research Prize

SPPH’s Dr. Patricia Janssen was on hand to present the inaugural Patricia Janssen Research Prize to midwifery student, Elizabeth Morrison

Dr. Clyde Hertzman honoured with the Champion of Human Services Award

Dr. Clyde Hertzman honoured with the Champion of Human Services Award

Dr. Clyde Hertzman was honoured with the Champion of Human Services Award by the Board of Directors of the Ontario Municipal Social Services Association (OMSSA).

Dr. Larry Frank

Obesity ruled a disease by the American Medical Association

Dr. Larry Frank discussed the ruling from an urban planning perspective

The graveyard shift

The graveyard shift

Study looks to improve sleep for shiftworkers and reduce the risk of cancer.

Harnessing the energy for curricular change in the School of Population and Public Health

Dr. Gary Poole discussed the School’s work on curricular change in the recent edition of Education Matters

PhD student Elaine Fuertes wins best abstract award at 6th European Public Health Conference

PhD student Elaine Fuertes wins best abstract award at 6th European Public Health Conference

SPPH PhD Student Elaine Fuertes’ abstract was awarded the “highest scoring abstract” award at the 6th European Public Health Conference

Questioning the value of expensive arthritis drugs

Questioning the value of expensive arthritis drugs

UBC health economist Aslam Anis comments on the value of biologics, a new class of rheumatoid arthritis drugs